- cafead   May 08, 2019 at 05:22: PM
via The US House of Representatives on Wednesday unanimously passed two bills that would increase the utility of the US Food and Drug Administration’s (FDA) Orange Book for generic drugmakers and Purple Book for biosimilar developers.
article source
article source